Acute/subacute herpes zoster: Healthcare resource utilisation and costs in a group of US health plans

PharmacoEconomics

Volumn 25, Issue 2, 2007, Pages 155-169

  Insinga, Ralph P ^a   Itzler, Robbin F ^a   Pellissier, James M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIPRURITIC AGENT; ANTIVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID DERIVATIVE; FAMCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; VALACICLOVIR; VIDARABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HERPES ZOSTER; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; OUTPATIENT; PAIN; PRESCRIPTION; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HEALTH SERVICES; HERPES ZOSTER; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; UNITED STATES;

EID: 33846601290     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725020-00007     Document Type: Article

References (51)

1. Gnann JW, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347: 340-6
2. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748-53
3. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191: 2002-7
4. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-9
5. Fleming DM, Cross KW, Cobb WA, et al. Gender difference in the incidence of shingles. Epidemiol Infect 2004; 132: 1-5
6. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 370-5
7. Smith JB, Fenske NA. Herpes zoster and internal malignancy. South Med J 1995; 88: 1089-92
8. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33: 62-9
9. Galil K, Choo PW, Donahue JG, et al. The sequelae of herpes zoster. Arch Intern Med 1997; 157: 1209-13
10. Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321: 794-6
11. Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage 2000; 20: 50-8
12. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36: 877-82
13. Lydick E, Epstein RS, Himmelberger D, et al. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45: S52-53
14. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5 (6): 344-56
15. Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis 2002; 186 Suppl. 1: S83-90
16. Davies L, Cossins L, Bowsher D, et al. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics 1994; 6: 142-8
17. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157: 1217-24
18. Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-51
19. Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70 Suppl. 1: S24-30
20. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84
21. Gnann JW. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl. 1: S91-8
22. Severson EA, Baratz KH, Hodge DO, et al. Herpes zoster ophthalmicus in olmsted county, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol 2003; 121: 386-90
23. Coplan P, Black S, Rojas C, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J 2001; 20: 641-5
24. DesHarnais S, Simpson KN, Paul JE. Variations in practice patterns: antiviral drug use in hospitalized patients with herpes infections. Am J Med Qual 1996; 11: 33-42
25. Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health 1988; 78: 19-23
26. Grant DM, Mauskopf JA, Bell L, et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy 1997; 17: 333-41
27. Paul JE, Mauskopf JA, Bell L. Cost-consequence models for varicella-zoster virus infections. Pharmacotherapy 1995; 15: 49S-58S
28. Huse DM, Schainbaum S, Kirsch AJ, et al. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Am J Health Syst Pharm 1997; 54: 1180-4
29. Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty? J Infect Dis 1998; 178 Suppl. 1: S85-90
30. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005; 65 (3): 444-7
31. Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 2001; 20: 2429-39
32. White RR, Lenhart G, Singhal PK, et al. Annual healthcare costs of herpes zoster (shingles) and its complications. 12th International Congress on Infectious Diseases; 2006 Jun 17, Lisbon
33. Mullooly JP, Riedlinger K, Chun C, et al. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133: 245-53
34. Itzler R, Choo P, Bauer M, et al. Comparison of patient self-reported healthcare resource utilization to electronic record data: lessons learned from a study of herpes zoster patients [abstract]. Value Health 2003; 6: 179
35. Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: 108-15
36. Engels EA, Rosenberg PS, Biggar RJ. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997: District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study. J Infect Dis 1999; 180: 1784-9
37. US Department of Labor. Consumer price index: medical care. Washington, DC: Bureau of Labor Statistics, 2006
38. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999; 20: 125-44
39. Huber PJ. Robust statistics. New York: John Wiley, 1981
40. Centers for Disease Control and Prevention. CDC WONDER: resident population estimates of the United States by age and sex [online]. Available from URL: http://wonder.cdc.gov/census.html [Accessed 2004 Mar 15]
41. Johnson R. Herpes zoster: predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother 2001; 47 Suppl. T1: 1-8
42. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863-9
43. Opstelten W, van Essen GA, Moons KG, et al. Do herpes zoster patients receive antivirals? A Dutch national survey in general practice. Fam Pract 2005; 22: 523-8
44. Dworkin RH, Nagasako EM, Johnson RW, et al. Acute pain in herpes zoster: the famciclovir database project. Pain 2001; 94: 113-9
45. Adour KK. Otological complications of herpes zoster. Ann Neurol 1994; 35 Suppl.: S62-4
46. Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12-6
47. Meister W, Neiss A, Gross G, et al. Demography, symptomatology, and course of disease in ambulatory zoster patients: a physician-based survey in Germany. Intervirology 1998; 41: 272-7
48. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2005; 24 (9): 1308-14
49. National Center for Health Statistics. Health, United States, 2005. Hyattsville (MD): National Center for Health Statistics, 2005
50. Gilden DH. Varicella-zoster virus vaccine: grown-ups need it, too. N Engl J Med 2005; 352: 2344-6
51. Kessler KM. A vaccine to prevent herpes zoster. N Engl J Med 2005; 353: 1414-5